Rocket Pharmaceuticals (RCKT) Expected to Announce Earnings on Monday

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) will likely be announcing its Q1 2025 earnings results before the market opens on Monday, May 5th. Analysts expect the company to announce earnings of ($0.59) per share and revenue of $0.80 million for the quarter.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last announced its earnings results on Monday, March 3rd. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.68) by $0.06. On average, analysts expect Rocket Pharmaceuticals to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Rocket Pharmaceuticals Price Performance

RCKT traded up $0.35 during midday trading on Wednesday, hitting $7.63. The company had a trading volume of 1,997,443 shares, compared to its average volume of 1,338,416. The company has a market capitalization of $813.59 million, a PE ratio of -2.77 and a beta of 1.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 6.05 and a current ratio of 6.05. The firm's 50-day simple moving average is $7.44 and its 200-day simple moving average is $11.20. Rocket Pharmaceuticals has a twelve month low of $4.55 and a twelve month high of $26.98.

Insider Activity at Rocket Pharmaceuticals

In related news, CEO Gaurav Shah purchased 20,000 shares of the firm's stock in a transaction that occurred on Thursday, April 10th. The stock was acquired at an average price of $5.08 per share, for a total transaction of $101,600.00. Following the completion of the acquisition, the chief executive officer now owns 792,680 shares of the company's stock, valued at $4,026,814.40. This represents a 2.59 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kinnari Patel bought 21,099 shares of the company's stock in a transaction on Wednesday, April 9th. The stock was bought at an average price of $4.70 per share, for a total transaction of $99,165.30. Following the completion of the purchase, the insider now owns 26,774 shares of the company's stock, valued at approximately $125,837.80. The trade was a 371.79 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 28.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Scotiabank lifted their price target on shares of Rocket Pharmaceuticals from $51.00 to $52.00 and gave the stock a "sector outperform" rating in a research report on Monday, March 3rd. The Goldman Sachs Group dropped their price target on Rocket Pharmaceuticals from $29.00 to $15.00 and set a "neutral" rating on the stock in a research report on Monday, March 3rd. BMO Capital Markets began coverage on Rocket Pharmaceuticals in a research report on Wednesday, March 12th. They issued an "outperform" rating and a $50.00 price objective for the company. Canaccord Genuity Group dropped their target price on shares of Rocket Pharmaceuticals from $39.00 to $36.00 and set a "buy" rating on the stock in a report on Monday, March 3rd. Finally, Chardan Capital cut their price target on shares of Rocket Pharmaceuticals from $62.00 to $54.00 and set a "buy" rating on the stock in a research note on Friday, February 28th. One analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, Rocket Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $43.00.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.